Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Colorectal Neoplasms

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 208 articles: HTML format

Single Articles

July 2021
1. FURTADO FS, Suarez-Weiss KE, Vangel M, Clark JW, et al
   Clinical impact of PET/MRI in oligometastatic colorectal cancer.
   Br J Cancer. 2021 Jul 19. pii: 10.1038/s41416-021-01494.
   PubMed     Abstract available
   
   
   
2. ZOLTICK ES, Smith-Warner SA, Yuan C, Wang M, et al
   Sugar-sweetened beverage, artificially sweetened beverage and sugar intake and colorectal cancer survival.
   Br J Cancer. 2021 Jul 15. pii: 10.1038/s41416-021-01487.
   PubMed     Abstract available
   
   
   
3. TEN HOORN S, Sommeijer DW, Elliott F, Fisher D, et al
   Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone.
   Br J Cancer. 2021 Jul 12. pii: 10.1038/s41416-021-01477.
   PubMed     Abstract available
   
   
   
4. WANG X, Liu Q, Halfdanarson OO, Zoega H, et al
   Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study.
   Br J Cancer. 2021 Jul 12. pii: 10.1038/s41416-021-01480.
   PubMed     Abstract available
   
   
   
5. MORETTO R, Rossini D, Conca V, Lonardi S, et al
   CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
   Br J Cancer. 2021 Jul 12. pii: 10.1038/s41416-021-01483.
   PubMed     Abstract available
   
   
   
6. HUA X, Kratz M, Malen RC, Dai JY, et al
   Association between post-treatment circulating biomarkers of inflammation and survival among stage II-III colorectal cancer patients.
   Br J Cancer. 2021 Jul 6. pii: 10.1038/s41416-021-01458.
   PubMed     Abstract available
   
   
   June 2021
7. LEE KH, Chen WS, Jiang JK, Yang SH, et al
   The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon.
   Br J Cancer. 2021 Jun 29. pii: 10.1038/s41416-021-01470.
   PubMed     Abstract available
   
   
   
8. LIN M, Fang Y, Li Z, Li Y, et al
   S100P contributes to promoter demethylation and transcriptional activation of SLC2A5 to promote metastasis in colorectal cancer.
   Br J Cancer. 2021 Jun 29. pii: 10.1038/s41416-021-01306.
   PubMed     Abstract available
   
   
   
9. GUO F, De Brabander I, Francart J, Candeur M, et al
   Correction: Benefits of switching from guaiac-based faecal occult blood to faecal immunochemical testing: experience from the Wallonia-Brussels colorectal cancer screening programme.
   Br J Cancer. 2021 Jun 28. pii: 10.1038/s41416-021-01468.
   PubMed    
   
   
   
10. SEFRIOUI D, Beaussire L, Gillibert A, Blanchard F, et al
    CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC).
    Br J Cancer. 2021 Jun 10. pii: 10.1038/s41416-021-01431.
    PubMed     Abstract available
    
    
    May 2021
11. OUAHOUD S, Jacobs RJ, Peppelenbosch MP, Fuhler GM, et al
    Correction: Kinome-wide analysis of the effect of statins in colorectal cancer.
    Br J Cancer. 2021 May 10. pii: 10.1038/s41416-021-01426.
    PubMed    
    
    
    
12. SALVIANTI F, Gelmini S, Mancini I, Pazzagli M, et al
    Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study.
    Br J Cancer. 2021 May 5. pii: 10.1038/s41416-021-01399.
    PubMed     Abstract available
    
    
    
13. FRIEND T, Stebbing J
    Profiling circulating tumour cells and cell free DNA together in metastatic colon cancer.
    Br J Cancer. 2021 May 5. pii: 10.1038/s41416-021-01397.
    PubMed     Abstract available
    
    
    April 2021
14. CHEN KH, Lin LI, Yuan CT, Tseng LH, et al
    Association between risk factors, molecular features and CpG island methylator phenotype colorectal cancer among different age groups in a Taiwanese cohort.
    Br J Cancer. 2021 Apr 12. pii: 10.1038/s41416-021-01300.
    PubMed     Abstract available
    
    
    
15. LUND CM, Vistisen KK, Olsen AP, Bardal P, et al
    The effect of geriatric intervention in frail older patients receiving chemotherapy for colorectal cancer: a randomised trial (GERICO).
    Br J Cancer. 2021 Apr 7. pii: 10.1038/s41416-021-01367.
    PubMed     Abstract available
    
    
    
16. KIM DW, Tan E, Zhou JM, Schell MJ, et al
    A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer.
    Br J Cancer. 2021 Apr 7. pii: 10.1038/s41416-021-01368.
    PubMed     Abstract available
    
    
    
17. BAXTER MA, Murphy J, Cameron D, Jordan J, et al
    The impact of COVID-19 on systemic anticancer treatment delivery in Scotland.
    Br J Cancer. 2021;124:1353-1356.
    PubMed     Abstract available
    
    
    
18. KREGTING LM, Kaljouw S, de Jonge L, Jansen EEL, et al
    Effects of cancer screening restart strategies after COVID-19 disruption.
    Br J Cancer. 2021;124:1516-1523.
    PubMed     Abstract available
    
    
    March 2021
19. FEARON DT, Janowitz T
    AMD3100/Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells.
    Br J Cancer. 2021 Mar 26. pii: 10.1038/s41416-021-01315.
    PubMed     Abstract available
    
    
    
20. GOLDER AM, McMillan DC, Park JH, Mansouri D, et al
    The prognostic value of combined measures of the systemic inflammatory response in patients with colon cancer: an analysis of 1700 patients.
    Br J Cancer. 2021 Mar 24. pii: 10.1038/s41416-021-01308.
    PubMed     Abstract available
    
    
    
21. OUAHOUD S, Jacobs RJ, Peppelenbosch MP, Fuhler GM, et al
    Kinome-wide analysis of the effect of statins in colorectal cancer.
    Br J Cancer. 2021 Mar 19. pii: 10.1038/s41416-021-01318.
    PubMed     Abstract available
    
    
    
22. ROSENDAHL HUBER A, Pleguezuelos-Manzano C, Puschhof J
    A bacterial mutational footprint in colorectal cancer genomes.
    Br J Cancer. 2021 Mar 19. pii: 10.1038/s41416-021-01273.
    PubMed     Abstract available
    
    
    
23. YAEGASHI M, Iwaya T, Sasaki N, Fujita M, et al
    Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling.
    Br J Cancer. 2021 Mar 3. pii: 10.1038/s41416-021-01266.
    PubMed     Abstract available
    
    
    February 2021
24. SHANG Y, Zhang X, Lu L, Jiang K, et al
    Pharmaceutical immunoglobulin G impairs anti-carcinoma activity of oxaliplatin in colon cancer cells.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01272.
    PubMed     Abstract available
    
    
    
25. PINTO-FERNANDEZ A, Salio M, Partridge T, Chen J, et al
    Deletion of the deISGylating enzyme USP18 enhances tumour cell antigenicity and radiosensitivity.
    Br J Cancer. 2021;124:817-830.
    PubMed     Abstract available
    
    
    January 2021
26. ZHANG X, Theodoratou E, Li X, Farrington SM, et al
    Genetically predicted physical activity levels are associated with lower colorectal cancer risk: a Mendelian randomisation study.
    Br J Cancer. 2021 Jan 29. pii: 10.1038/s41416-020-01236.
    PubMed     Abstract available
    
    
    
27. BAILEY SER, Abel GA, Atkins A, Byford R, et al
    Diagnostic performance of a faecal immunochemical test for patients with low-risk symptoms of colorectal cancer in primary care: an evaluation in the South West of England.
    Br J Cancer. 2021 Jan 19. pii: 10.1038/s41416-020-01221.
    PubMed     Abstract available
    
    
    
28. UENO H, Ishiguro M, Nakatani E, Ishikawa T, et al
    Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a Phase 3 study (SACURA Trial).
    Br J Cancer. 2021 Jan 7. pii: 10.1038/s41416-020-01222.
    PubMed     Abstract available
    
    
    
29. CULLIFORD R, Cornish AJ, Law PJ, Farrington SM, et al
    Lack of an association between gallstone disease and bilirubin levels with risk of colorectal cancer: a Mendelian randomisation analysis.
    Br J Cancer. 2021 Jan 7. pii: 10.1038/s41416-020-01211.
    PubMed     Abstract available
    
    
    
30. BRAGAGNOLI AC, Araujo RLC, Ferraz MW, Dos Santos LV, et al
    Metformin plus lrinotecan in patients with refractory colorectal cancer: a phase 2 clinical trial.
    Br J Cancer. 2021 Jan 4. pii: 10.1038/s41416-020-01208.
    PubMed     Abstract available
    
    
    December 2020
31. LOUGHREY MB, Fisher NC, McCooey AJ, Dunne PD, et al
    Comment on "Identification of EMT-related high-risk stage II colorectal cancer and characterisation of metastasis-related genes".
    Br J Cancer. 2020 Dec 14. pii: 10.1038/s41416-020-01213.
    PubMed    
    
    
    
32. YASUI K, Shida D, Nakamura Y, Ahiko Y, et al
    Postoperative, but not preoperative, inflammation-based prognostic markers are prognostic factors in stage III colorectal cancer patients.
    Br J Cancer. 2020 Dec 1. pii: 10.1038/s41416-020-01189.
    PubMed     Abstract available
    
    
    
33. ZELLWEGER M, Gonzalez M
    Comment on: the myth of pulmonary metastasectomy.
    Br J Cancer. 2020;123:1833-1834.
    PubMed    
    
    
    
34. MACBETH F, Fallowfield DL
    Reply to 'Comment on "The myth of pulmonary metastasectomy'".
    Br J Cancer. 2020;123:1835-1836.
    PubMed    
    
    
    November 2020
35. YU J, Li S, Xu Z, Guo J, et al
    CDX2 inhibits epithelial-mesenchymal transition in colorectal cancer by modulation of Snail expression and beta-catenin stabilisation via transactivation of PTEN expression.
    Br J Cancer. 2020 Nov 26. pii: 10.1038/s41416-020-01148.
    PubMed     Abstract available
    
    
    
36. ALEXANDER PG, Roseweir AK, Pennel KAF, van Wyk HC, et al
    The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer.
    Br J Cancer. 2020 Nov 23. pii: 10.1038/s41416-020-01168.
    PubMed     Abstract available
    
    
    
37. JACOME AA, Vreeland TJ, Johnson B, Kawaguchi Y, et al
    The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients.
    Br J Cancer. 2020 Nov 19. pii: 10.1038/s41416-020-01169.
    PubMed     Abstract available
    
    
    
38. HUIJBERTS SCFA, Boelens MC, Bernards R, Opdam FL, et al
    Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib.
    Br J Cancer. 2020 Nov 18. pii: 10.1038/s41416-020-01147.
    PubMed     Abstract available
    
    
    
39. HEINEMANN V, von Weikersthal LF, Decker T, Kiani A, et al
    FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
    Br J Cancer. 2020 Nov 6. pii: 10.1038/s41416-020-01140.
    PubMed     Abstract available
    
    
    
40. FANG Z, He M, Song M
    Serum lipid profiles and risk of colorectal cancer: a prospective cohort study in the UK Biobank.
    Br J Cancer. 2020 Nov 3. pii: 10.1038/s41416-020-01143.
    PubMed     Abstract available
    
    
    
41. LI YY, Gao LJ, Zhang YX, Liu SJ, et al
    Bisphosphonates and risk of cancers: a systematic review and meta-analysis.
    Br J Cancer. 2020;123:1570-1581.
    PubMed     Abstract available
    
    
    October 2020
42. CHA PH, Hwang JH, Kwak DK, Koh E, et al
    APC loss induces Warburg effect via increased PKM2 transcription in colorectal cancer.
    Br J Cancer. 2020 Oct 19. pii: 10.1038/s41416-020-01118.
    PubMed     Abstract available
    
    
    
43. WENSINK GE, Elferink MAG, May AM, Mol L, et al
    Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era.
    Br J Cancer. 2020 Oct 13. pii: 10.1038/s41416-020-01076.
    PubMed     Abstract available
    
    
    
44. ROSSINI D, Lonardi S, Antoniotti C, Santini D, et al
    Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01089.
    PubMed     Abstract available
    
    
    
45. HE F, Ju HQ, Ding Y, Jiang Z, et al
    Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection.
    Br J Cancer. 2020;123:1244-1252.
    PubMed     Abstract available
    
    
    September 2020
46. SIMIN J, Fornes R, Liu Q, Olsen RS, et al
    Antibiotic use and risk of colorectal cancer: a systematic review and dose-response meta-analysis.
    Br J Cancer. 2020 Sep 24. pii: 10.1038/s41416-020-01082.
    PubMed     Abstract available
    
    
    
47. VAUGHAN-SHAW PG, Buijs LF, Blackmur JP, Theodoratou E, et al
    The effect of vitamin D supplementation on survival in patients with colorectal cancer: systematic review and meta-analysis of randomised controlled trials.
    Br J Cancer. 2020 Sep 15. pii: 10.1038/s41416-020-01060.
    PubMed     Abstract available
    
    
    
48. PAPE J, Magdeldin T, Stamati K, Nyga A, et al
    Cancer-associated fibroblasts mediate cancer progression and remodel the tumouroid stroma.
    Br J Cancer. 2020;123:1178-1190.
    PubMed     Abstract available
    
    
    
49. MURAHASHI S, Akiyoshi T, Sano T, Fukunaga Y, et al
    Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence.
    Br J Cancer. 2020;123:803-810.
    PubMed     Abstract available
    
    
    August 2020
50. MASUISHI T, Tsuji A, Kotaka M, Nakamura M, et al
    Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08.
    Br J Cancer. 2020 Aug 31. pii: 10.1038/s41416-020-01042.
    PubMed     Abstract available
    
    
    
51. COWLING TE, Bellot A, Boyle J, Walker K, et al
    One-year mortality of colorectal cancer patients: development and validation of a prediction model using linked national electronic data.
    Br J Cancer. 2020 Aug 24. pii: 10.1038/s41416-020-01034.
    PubMed     Abstract available
    
    
    
52. KIM TW, Lee YS, Yun NH, Shin CH, et al
    Correction: MicroRNA-17-5p regulates EMT by targeting vimentin in colorectal cancer.
    Br J Cancer. 2020 Aug 20. pii: 10.1038/s41416-020-1027.
    PubMed     Abstract available
    
    
    
53. MACBETH F, Fallowfield L
    The myth of pulmonary metastasectomy.
    Br J Cancer. 2020;123:499-500.
    PubMed     Abstract available
    
    
    July 2020
54. RAGHAV K, Shen JP, Jacome AA, Guerra JL, et al
    Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer.
    Br J Cancer. 2020 Jul 31. pii: 10.1038/s41416-020-1015.
    PubMed     Abstract available
    
    
    
55. CRAIG SG, Humphries MP, Alderdice M, Bingham V, et al
    Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia.
    Br J Cancer. 2020 Jul 20. pii: 10.1038/s41416-020-0985.
    PubMed     Abstract available
    
    
    
56. YANG L, Chen P, Zhang L, Wang L, et al
    Prognostic value of nucleotyping, DNA ploidy and stroma in high-risk stage II colon cancer.
    Br J Cancer. 2020 Jul 6. pii: 10.1038/s41416-020-0974.
    PubMed     Abstract available
    
    
    
57. YUAN C, Ng K
    Vitamin D supplementation: a potential therapeutic agent for metastatic colorectal cancer.
    Br J Cancer. 2020 Jul 6. pii: 10.1038/s41416-020-0958.
    PubMed     Abstract available
    
    
    
58. HOPPENER DJ, Nierop PMH, Hof J, Sideras K, et al
    Enrichment of the tumour immune microenvironment in patients with desmoplastic colorectal liver metastasis.
    Br J Cancer. 2020;123:196-206.
    PubMed     Abstract available
    
    
    June 2020
59. IWAMOTO K, Takahashi H, Okuzaki D, Osawa H, et al
    Syntenin-1 promotes colorectal cancer stem cell expansion and chemoresistance by regulating prostaglandin E2 receptor.
    Br J Cancer. 2020 Jun 29. pii: 10.1038/s41416-020-0965.
    PubMed     Abstract available
    
    
    
60. KIM TW, Lee YS, Yun NH, Shin CH, et al
    MicroRNA-17-5p regulates EMT by targeting vimentin in colorectal cancer.
    Br J Cancer. 2020 Jun 17. pii: 10.1038/s41416-020-0940.
    PubMed     Abstract available
    
    
    
61. BABIC A, Zhang X, Morales-Oyarvide V, Yuan C, et al
    Acid-suppressive medications and risk of colorectal cancer: results from three large prospective cohort studies.
    Br J Cancer. 2020 Jun 16. pii: 10.1038/s41416-020-0939.
    PubMed     Abstract available
    
    
    
62. PERNOT S, Pellerin O, Artru P, Monterymard C, et al
    Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study.
    Br J Cancer. 2020 Jun 8. pii: 10.1038/s41416-020-0917.
    PubMed     Abstract available
    
    
    
63. PARK JW, Chang HJ, Yeo HY, Han N, et al
    The relationships between systemic cytokine profiles and inflammatory markers in colorectal cancer and the prognostic significance of these parameters.
    Br J Cancer. 2020 Jun 3. pii: 10.1038/s41416-020-0924.
    PubMed     Abstract available
    
    
    
64. ROOS VH, Kallenberg FGJ, van der Vlugt M, Bongers EJC, et al
    Addition of an online, validated family history questionnaire to the Dutch FIT-based screening programme did not improve its diagnostic yield.
    Br J Cancer. 2020;122:1865-1871.
    PubMed     Abstract available
    
    
    May 2020
65. RAY AL, Nofchissey RA, Khan MA, Reidy MA, et al
    The role of sex in the innate and adaptive immune environment of metastatic colorectal cancer.
    Br J Cancer. 2020 May 26. pii: 10.1038/s41416-020-0913.
    PubMed     Abstract available
    
    
    
66. WANG K, Song K, Ma Z, Yao Y, et al
    Identification of EMT-related high-risk stage II colorectal cancer and characterisation of metastasis-related genes.
    Br J Cancer. 2020 May 21. pii: 10.1038/s41416-020-0902.
    PubMed     Abstract available
    
    
    
67. FUCA G, Guarini V, Antoniotti C, Morano F, et al
    The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials.
    Br J Cancer. 2020 May 19. pii: 10.1038/s41416-020-0894.
    PubMed     Abstract available
    
    
    
68. LOKTIONOV A, Soubieres A, Bandaletova T, Francis N, et al
    Biomarker measurement in non-invasively sampled colorectal mucus as a novel approach to colorectal cancer detection: screening and triage implications.
    Br J Cancer. 2020 May 13. pii: 10.1038/s41416-020-0893.
    PubMed     Abstract available
    
    
    
69. STREMITZER S, Vermeulen P, Graver S, Kockx M, et al
    Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases.
    Br J Cancer. 2020;122:1518-1524.
    PubMed     Abstract available
    
    
    
70. QIN B, Zou S, Li K, Wang H, et al
    CSN6-TRIM21 axis instigates cancer stemness during tumorigenesis.
    Br J Cancer. 2020;122:1673-1685.
    PubMed     Abstract available
    
    
    April 2020
71. BARISCIANO G, Colangelo T, Rosato V, Muccillo L, et al
    Correction: miR-27a is a master regulator of metabolic reprogramming and chemoresistance in colorectal cancer.
    Br J Cancer. 2020 Apr 17. pii: 10.1038/s41416-020-0855.
    PubMed     Abstract available
    
    
    
72. DAI W, Wang G, Chwa J, Oh ME, et al
    Mitochondrial division inhibitor (mdivi-1) decreases oxidative metabolism in cancer.
    Br J Cancer. 2020;122:1288-1297.
    PubMed     Abstract available
    
    
    
73. VAN GEEL RMJM, van Brummelen EMJ, Eskens FALM, Huijberts SCFA, et al
    Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
    Br J Cancer. 2020;122:1166-1174.
    PubMed     Abstract available
    
    
    March 2020
74. MILANO G, Gal J
    Comment on: "Exploring the best treatment options for BRAF-mutant metastatic colon cancer".
    Br J Cancer. 2020 Mar 31. pii: 10.1038/s41416-020-0819.
    PubMed    
    
    
    
75. AMITAY EL, Carr PR, Jansen L, Roth W, et al
    Smoking, alcohol consumption and colorectal cancer risk by molecular pathological subtypes and pathways.
    Br J Cancer. 2020 Mar 30. pii: 10.1038/s41416-020-0803.
    PubMed     Abstract available
    
    
    
76. WANG X, Li D, Sun L, Shen G, et al
    Regulation of the small GTPase Ran by miR-802 modulates proliferation and metastasis in colorectal cancer cells.
    Br J Cancer. 2020 Mar 25. pii: 10.1038/s41416-020-0809.
    PubMed     Abstract available
    
    
    
77. YUAN Z, Liang X, Zhan Y, Wang Z, et al
    Targeting CD133 reverses drug-resistance via the AKT/NF-kappaB/MDR1 pathway in colorectal cancer.
    Br J Cancer. 2020 Mar 16. pii: 10.1038/s41416-020-0783.
    PubMed     Abstract available
    
    
    
78. USHER-SMITH JA, Harshfield A, Saunders CL, Sharp SJ, et al
    Correction: External validation of risk prediction models for incident colorectal cancer using UK Biobank.
    Br J Cancer. 2020 Mar 12. pii: 10.1038/s41416-020-0767.
    PubMed     Abstract available
    
    
    
79. HARUKI K, Kosumi K, Li P, Arima K, et al
    An integrated analysis of lymphocytic reaction, tumour molecular characteristics and patient survival in colorectal cancer.
    Br J Cancer. 2020 Mar 11. pii: 10.1038/s41416-020-0780.
    PubMed     Abstract available
    
    
    
80. BARNES EME, Xu Y, Benito A, Herendi L, et al
    Lactic acidosis induces resistance to the pan-Akt inhibitor uprosertib in colon cancer cells.
    Br J Cancer. 2020 Mar 10. pii: 10.1038/s41416-020-0777.
    PubMed     Abstract available
    
    
    
81. BARISCIANO G, Colangelo T, Rosato V, Muccillo L, et al
    miR-27a is a master regulator of metabolic reprogramming and chemoresistance in colorectal cancer.
    Br J Cancer. 2020 Mar 5. pii: 10.1038/s41416-020-0773.
    PubMed     Abstract available
    
    
    
82. OTANDAULT A, Abraham JD, Al Amir Dache Z, Khalyfa A, et al
    Hypoxia differently modulates the release of mitochondrial and nuclear DNA.
    Br J Cancer. 2020;122:715-725.
    PubMed     Abstract available
    
    
    
83. HERIOT AG
    Whither Anal Cancer?
    Br J Cancer. 2020;122:733-734.
    PubMed     Abstract available
    
    
    
84. SEKHAR H, Malcomson L, Kochhar R, Sperrin M, et al
    Temporal improvements in loco-regional failure and survival in patients with anal cancer treated with chemo-radiotherapy: treatment cohort study (1990-2014).
    Br J Cancer. 2020;122:749-758.
    PubMed     Abstract available
    
    
    
85. APARICIO T, Bennouna J, Le Malicot K, Boige V, et al
    Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial.
    Br J Cancer. 2020;122:957-962.
    PubMed     Abstract available
    
    
    February 2020
86. BANDO H, Kagawa Y, Kato T, Akagi K, et al
    Correction: A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer.
    Br J Cancer. 2020 Feb 25. pii: 10.1038/s41416-020-0766.
    PubMed     Abstract available
    
    
    
87. MORIMOTO Y, Mizushima T, Wu X, Okuzaki D, et al
    miR-4711-5p regulates cancer stemness and cell cycle progression via KLF5, MDM2 and TFDP1 in colon cancer cells.
    Br J Cancer. 2020 Feb 18. pii: 10.1038/s41416-020-0758.
    PubMed     Abstract available
    
    
    
88. GUO F, De Brabander I, Francart J, Candeur M, et al
    Benefits of switching from guaiac-based faecal occult blood to faecal immunochemical testing: experience from the Wallonia-Brussels colorectal cancer screening programme.
    Br J Cancer. 2020 Feb 18. pii: 10.1038/s41416-020-0754.
    PubMed     Abstract available
    
    
    
89. VAN DE BEEK I, Glykofridis IE, Wolthuis RMF, Gille HJJP, et al
    No evidence for increased prevalence of colorectal carcinoma in 399 Dutch patients with Birt-Hogg-Dube syndrome.
    Br J Cancer. 2020;122:590-594.
    PubMed     Abstract available
    
    
    January 2020
90. ARMSTRONG D, Dregan A, Ashworth M, White P, et al
    The association between colorectal cancer and prior antibiotic prescriptions: case control study.
    Br J Cancer. 2020 Jan 13. pii: 10.1038/s41416-019-0701.
    PubMed     Abstract available
    
    
    
91. LIANG Y, Zhu D, Hou L, Wang Y, et al
    MiR-107 confers chemoresistance to colorectal cancer by targeting calcium-binding protein 39.
    Br J Cancer. 2020 Jan 10. pii: 10.1038/s41416-019-0703.
    PubMed     Abstract available
    
    
    December 2019
92. HOU P, Shi P, Jiang T, Yin H, et al
    DKC1 enhances angiogenesis by promoting HIF-1alpha transcription and facilitates metastasis in colorectal cancer.
    Br J Cancer. 2019 Dec 20. pii: 10.1038/s41416-019-0695.
    PubMed     Abstract available
    
    
    
93. WU L, Zhou Z, Han S, Chen J, et al
    PLAGL2 promotes epithelial-mesenchymal transition and mediates colorectal cancer metastasis via beta-catenin-dependent regulation of ZEB1.
    Br J Cancer. 2019 Dec 12. pii: 10.1038/s41416-019-0679.
    PubMed     Abstract available
    
    
    
94. FU M, Chen D, Luo F, Li M, et al
    Association of the tumour stroma percentage in the preoperative biopsies with lymph node metastasis in colorectal cancer.
    Br J Cancer. 2019 Dec 2. pii: 10.1038/s41416-019-0671.
    PubMed     Abstract available
    
    
    October 2019
95. KUWAHARA T, Hazama S, Suzuki N, Yoshida S, et al
    Correction: Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer.
    Br J Cancer. 2019 Oct 17. pii: 10.1038/s41416-019-0605.
    PubMed     Abstract available
    
    
    
96. SAHIN IH, Akce M, Alese O, Shaib W, et al
    Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms.
    Br J Cancer. 2019 Oct 14. pii: 10.1038/s41416-019-0599.
    PubMed     Abstract available
    
    
    September 2019
97. CIRONE M, Lotti LV, Granato M, Renzo LD, et al
    Sourcing the immune system to induce immunogenic cell death in Kras-colorectal cancer cells.
    Br J Cancer. 2019 Sep 27. pii: 10.1038/s41416-019-0561.
    PubMed     Abstract available
    
    
    
98. DASHTI SG, Li WY, Buchanan DD, Clendenning M, et al
    Type 2 diabetes mellitus, blood cholesterol, triglyceride and colorectal cancer risk in Lynch syndrome.
    Br J Cancer. 2019 Sep 25. pii: 10.1038/s41416-019-0580.
    PubMed     Abstract available
    
    
    
99. GLAIRE MA, Domingo E, Sveen A, Bruun J, et al
    Correction: Tumour-infiltrating CD8(+) lymphocytes and colorectal cancer recurrence by tumour and nodal stage.
    Br J Cancer. 2019 Sep 23. pii: 10.1038/s41416-019-0590.
    PubMed     Abstract available
    
    
    
100. ZHAO J, Giri A, Zhu X, Shrubsole MJ, et al
     Calcium: magnesium intake ratio and colorectal carcinogenesis, results from the prostate, lung, colorectal, and ovarian cancer screening trial.
     Br J Cancer. 2019 Sep 23. pii: 10.1038/s41416-019-0579.
     PubMed     Abstract available
     
     
     
101. KUWAHARA T, Hazama S, Suzuki N, Yoshida S, et al
     Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer.
     Br J Cancer. 2019 Sep 6. pii: 10.1038/s41416-019-0559.
     PubMed     Abstract available
     
     
     
102. LOUPAKIS F, Biason P, Prete AA, Cremolini C, et al
     CK7 and consensus molecular subtypes as major prognosticators in (V600E)BRAF mutated metastatic colorectal cancer.
     Br J Cancer. 2019 Sep 2. pii: 10.1038/s41416-019-0560.
     PubMed     Abstract available
     
     
     August 2019
103. KORPHAISARN K, Morris V, Davis JS, Overman MJ, et al
     Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma.
     Br J Cancer. 2019 Aug 13. pii: 10.1038/s41416-019-0548.
     PubMed     Abstract available
     
     
     
104. GLAIRE MA, Domingo E, Sveen A, Bruun J, et al
     Tumour-infiltrating CD8(+) lymphocytes and colorectal cancer recurrence by tumour and nodal stage.
     Br J Cancer. 2019 Aug 7. pii: 10.1038/s41416-019-0540.
     PubMed     Abstract available
     
     
     July 2019
105. ELEZ E, Pericay C, Valladares-Ayerbes M, Bando I, et al
     A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients.
     Br J Cancer. 2019 Jul 31. pii: 10.1038/s41416-019-0537.
     PubMed     Abstract available
     
     
     
106. PFUDERER PL, Ballhausen A, Seidler F, Stark HJ, et al
     High endothelial venules are associated with microsatellite instability, hereditary background and immune evasion in colorectal cancer.
     Br J Cancer. 2019 Jul 30. pii: 10.1038/s41416-019-0514.
     PubMed     Abstract available
     
     
     
107. TAIEB J, Lapeyre-Prost A, Laurent Puig P, Zaanan A, et al
     Exploring the best treatment options for BRAF-mutant metastatic colon cancer.
     Br J Cancer. 2019 Jul 29. pii: 10.1038/s41416-019-0526.
     PubMed     Abstract available
     
     
     
108. GORBUNOVA V, Beck JT, Hofheinz RD, Garcia-Alfonso P, et al
     Correction: A phase 2 randomised study of veliparib plus FOLFIRI+/-bevacizumab versus placebo plus FOLFIRI+/-bevacizumab in metastatic colorectal cancer.
     Br J Cancer. 2019 Jul 26. pii: 10.1038/s41416-019-0528.
     PubMed     Abstract available
     
     
     
109. KROUPA M, Rachakonda SK, Liska V, Srinivas N, et al
     Relationship of telomere length in colorectal cancer patients with cancer phenotype and patient prognosis.
     Br J Cancer. 2019 Jul 17. pii: 10.1038/s41416-019-0525.
     PubMed     Abstract available
     
     
     
110. AUCLIN E, Andre T, Taieb J, Banzi M, et al
     Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial.
     Br J Cancer. 2019 Jul 12. pii: 10.1038/s41416-019-0521.
     PubMed     Abstract available
     
     
     
111. MEZHEYEUSKI A, Hrynchyk I, Herrera M, Karlberg M, et al
     Stroma-normalised vessel density predicts benefit from adjuvant fluorouracil-based chemotherapy in patients with stage II/III colon cancer.
     Br J Cancer. 2019 Jul 10. pii: 10.1038/s41416-019-0519.
     PubMed     Abstract available
     
     
     
112. OKI E, Emi Y, Yamanaka T, Uetake H, et al
     Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial).
     Br J Cancer. 2019;121:222-229.
     PubMed     Abstract available
     
     
     
113. REZENDE LFM, Lee DH, Keum N, Nimptsch K, et al
     Physical activity during adolescence and risk of colorectal adenoma later in life: results from the Nurses' Health Study II.
     Br J Cancer. 2019;121:86-94.
     PubMed     Abstract available
     
     
     May 2019
114. CHARITOU T, Srihari S, Lynn MA, Jarboui MA, et al
     Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRAS(G13D) mutation.
     Br J Cancer. 2019 May 28. pii: 10.1038/s41416-019-0477.
     PubMed     Abstract available
     
     
     
115. SYRIOPOULOU E, Morris E, Finan PJ, Lambert PC, et al
     Understanding the impact of socioeconomic differences in colorectal cancer survival: potential gain in life-years.
     Br J Cancer. 2019 May 1. pii: 10.1038/s41416-019-0455.
     PubMed     Abstract available
     
     
     April 2019
116. BANDO H, Kagawa Y, Kato T, Akagi K, et al
     A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer.
     Br J Cancer. 2019 Apr 24. pii: 10.1038/s41416-019-0457.
     PubMed     Abstract available
     
     
     
117. NAGATA H, Ishihara S, Abe H, Ushiku T, et al
     LGR5 expression predicts peritoneal recurrence after curative resection of primary colon cancer.
     Br J Cancer. 2019 Apr 19. pii: 10.1038/s41416-019-0442.
     PubMed     Abstract available
     
     
     
118. XU X, Zhu L, Yang Y, Pan Y, et al
     Low tumour PPM1H indicates poor prognosis in colorectal cancer via activation of cancer-associated fibroblasts.
     Br J Cancer. 2019 Apr 16. pii: 10.1038/s41416-019-0450.
     PubMed     Abstract available
     
     
     
119. MOON JH, Hong SW, Kim JE, Shin JS, et al
     Targeting beta-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations.
     Br J Cancer. 2019 Apr 4. pii: 10.1038/s41416-019-0434.
     PubMed     Abstract available
     
     
     
120. KATHER JN, Halama N
     Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer.
     Br J Cancer. 2019 Apr 2. pii: 10.1038/s41416-019-0441.
     PubMed     Abstract available
     
     
     
121. STROWITZKI MJ, Radhakrishnan P, Pavicevic S, Scheer J, et al
     High hepatic expression of PDK4 improves survival upon multimodal treatment of colorectal liver metastases.
     Br J Cancer. 2019;120:675-688.
     PubMed     Abstract available
     
     
     March 2019
122. OH HJ, Bae JM, Wen X, Jung S, et al
     p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
     Br J Cancer. 2019 Mar 21. pii: 10.1038/s41416-019-0429.
     PubMed     Abstract available
     
     
     
123. IJSSELSTEIJN ME, Petitprez F, Lacroix L, Ruano D, et al
     Revisiting immune escape in colorectal cancer in the era of immunotherapy.
     Br J Cancer. 2019 Mar 13. pii: 10.1038/s41416-019-0421.
     PubMed     Abstract available
     
     
     
124. TOMITA N, Kunieda K, Maeda A, Hamada C, et al
     Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study.
     Br J Cancer. 2019 Mar 5. pii: 10.1038/s41416-019-0410.
     PubMed     Abstract available
     
     
     
125. MARTIN V, Chiriaco C, Modica C, Acquadro A, et al
     Met inhibition revokes IFNgamma-induction of PD-1 ligands in MET-amplified tumours.
     Br J Cancer. 2019;120:527-536.
     PubMed     Abstract available
     
     
     February 2019
126. RASMUSSEN S, Haastrup PF, Balasubramaniam K, Elnegaard S, et al
     Predictive values of colorectal cancer alarm symptoms in the general population: a nationwide cohort study.
     Br J Cancer. 2019 Feb 22. pii: 10.1038/s41416-019-0385.
     PubMed     Abstract available
     
     
     January 2019
127. VARKARIS A, Katsiampoura A, Davis JS, Shah N, et al
     Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer.
     Br J Cancer. 2019 Jan 14. pii: 10.1038/s41416-018-0360.
     PubMed     Abstract available
     
     
     
128. GOEPPERT B, Roessler S, Renner M, Singer S, et al
     Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma.
     Br J Cancer. 2019;120:109-114.
     PubMed     Abstract available
     
     
     December 2018
129. PAEZ D, Tobena M, Fernandez-Plana J, Sebio A, et al
     Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.
     Br J Cancer. 2018 Dec 26. pii: 10.1038/s41416-018-0348.
     PubMed     Abstract available
     
     
     
130. CROSS AJ, Wooldrage K, Robbins EC, Pack K, et al
     Whole-colon investigation vs. flexible sigmoidoscopy for suspected colorectal cancer based on presenting symptoms and signs: a multicentre cohort study.
     Br J Cancer. 2018 Dec 19. pii: 10.1038/s41416-018-0335.
     PubMed     Abstract available
     
     
     
131. SIRNIO P, Vayrynen JP, Klintrup K, Makela J, et al
     Alterations in serum amino-acid profile in the progression of colorectal cancer: associations with systemic inflammation, tumour stage and patient survival.
     Br J Cancer. 2018 Dec 19. pii: 10.1038/s41416-018-0357.
     PubMed     Abstract available
     
     
     
132. WANG J, Shibayama Y, Zhang A, Ohsaki H, et al
     (Pro)renin receptor promotes colorectal cancer through the Wnt/beta-catenin signalling pathway despite constitutive pathway component mutations.
     Br J Cancer. 2018 Dec 17. pii: 10.1038/s41416-018-0350.
     PubMed     Abstract available
     
     
     
133. GORBUNOVA V, Beck JT, Hofheinz RD, Garcia-Alfonso P, et al
     A phase 2 randomised study of veliparib plus FOLFIRI+/-bevacizumab versus placebo plus FOLFIRI+/-bevacizumab in metastatic colorectal cancer.
     Br J Cancer. 2018 Dec 11. pii: 10.1038/s41416-018-0343.
     PubMed     Abstract available
     
     
     November 2018
134. LOUPAKIS F, Hurwitz HI, Saltz L, Arnold D, et al
     Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer.
     Br J Cancer. 2018 Nov 29. pii: 10.1038/s41416-018-0304.
     PubMed     Abstract available
     
     
     
135. GILBERT DC, Wakeham K, Langley RE, Vale CL, et al
     Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis.
     Br J Cancer. 2018 Nov 28. pii: 10.1038/s41416-018-0273.
     PubMed     Abstract available
     
     
     
136. GARCIA-FONCILLAS J, Tabernero J, Elez E, Aranda E, et al
     Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer.
     Br J Cancer. 2018 Nov 23. pii: 10.1038/s41416-018-0293.
     PubMed     Abstract available
     
     
     
137. HANSEN TF, Kjaer-Frifeldt S, Eriksen AC, Lindebjerg J, et al
     Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts.
     Br J Cancer. 2018 Nov 14. pii: 10.1038/s41416-018-0285.
     PubMed     Abstract available
     
     
     
138. ROBLES-ZURITA J, Boyd KA, Briggs AH, Iveson T, et al
     SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.
     Br J Cancer. 2018 Nov 13. pii: 10.1038/s41416-018-0319.
     PubMed     Abstract available
     
     
     
139. KIM BK, Nam SW, Min BS, Ban HS, et al
     Bcl-2-dependent synthetic lethal interaction of the IDF-11774 with the V0 subunit C of vacuolar ATPase (ATP6V0C) in colorectal cancer.
     Br J Cancer. 2018 Nov 13. pii: 10.1038/s41416-018-0289.
     PubMed     Abstract available
     
     
     
140. MA Y, Yang W, Song M, Smith-Warner SA, et al
     Type 2 diabetes and risk of colorectal cancer in two large U.S. prospective cohorts.
     Br J Cancer. 2018 Nov 7. pii: 10.1038/s41416-018-0314.
     PubMed     Abstract available
     
     
     
141. TRINH A, Ladrach C, Dawson HE, Ten Hoorn S, et al
     Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data.
     Br J Cancer. 2018 Nov 2. pii: 10.1038/s41416-018-0230.
     PubMed     Abstract available
     
     
     October 2018
142. SCHIFFMANN LM, Fritsch M, Gebauer F, Gunther SD, et al
     Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.
     Br J Cancer. 2018 Oct 31. pii: 10.1038/s41416-018-0198.
     PubMed     Abstract available
     
     
     
143. AL-SAFFAR NMS, Troy H, Wong Te Fong AC, Paravati R, et al
     Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma.
     Br J Cancer. 2018 Oct 31. pii: 10.1038/s41416-018-0242.
     PubMed     Abstract available
     
     
     
144. SMITH T, Gunter MJ, Tzoulaki I, Muller DC, et al
     The added value of genetic information in colorectal cancer risk prediction models: development and evaluation in the UK Biobank prospective cohort study.
     Br J Cancer. 2018 Oct 16. pii: 10.1038/s41416-018-0282.
     PubMed     Abstract available
     
     
     
145. BARTOLOME RA, Jaen M, Casal JI
     An IL13Ralpha2 peptide exhibits therapeutic activity against metastatic colorectal cancer.
     Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0259.
     PubMed     Abstract available
     
     
     
146. UZUNPARMAK B, Sahin IH
     Comment on "ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer".
     Br J Cancer. 2018 Oct 9. pii: 10.1038/s41416-018-0279.
     PubMed    
     
     
     
147. ROSEWEIR AK, McMillan DC, Edwards J
     Reply to comment of "ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer".
     Br J Cancer. 2018 Oct 9. pii: 10.1038/s41416-018-0275.
     PubMed    
     
     
     
148. HALIM S, Markert EK, Vazquez A
     Analysis of cell proliferation and tissue remodelling uncovers a KLF4 activity score associated with poor prognosis in colorectal cancer.
     Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0253.
     PubMed     Abstract available
     
     
     
149. BRENNER H, Chen C
     The colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention.
     Br J Cancer. 2018 Oct 4. pii: 10.1038/s41416-018-0264.
     PubMed     Abstract available
     
     
     
150. CARVAJAL-CARMONA LG
     Moving the needle on colorectal cancer genetics: it takes more than two to TANGO.
     Br J Cancer. 2018 Oct 4. pii: 10.1038/s41416-018-0219.
     PubMed    
     
     
     August 2018
151. THEODORATOU E, Farrington SM, Timofeeva M, Din FV, et al
     Genome-wide scan of the effect of common nsSNPs on colorectal cancer survival outcome.
     Br J Cancer. 2018 Aug 21. pii: 10.1038/s41416-018-0117.
     PubMed     Abstract available
     
     
     
152. MARINGE C, Rachet B, Lyratzopoulos G, Rubio FJ, et al
     Persistent inequalities in unplanned hospitalisation among colon cancer patients across critical phases of their care pathway, England, 2011-13.
     Br J Cancer. 2018 Aug 15. pii: 10.1038/s41416-018-0170.
     PubMed     Abstract available
     
     
     
153. SUGIMACHI K, Sakimura S, Kuramitsu S, Hirata H, et al
     Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy.
     Br J Cancer. 2018 Aug 3. pii: 10.1038/s41416-018-0208.
     PubMed     Abstract available
     
     
     
154. JUUL JS, Hornung N, Andersen B, Laurberg S, et al
     The value of using the faecal immunochemical test in general practice on patients presenting with non-alarm symptoms of colorectal cancer.
     Br J Cancer. 2018 Aug 1. pii: 10.1038/s41416-018-0178.
     PubMed     Abstract available
     
     
     July 2018
155. PERNOT S, Boucheron P, Pere H, Lucas ML, et al
     Comparison of anal cancer screening strategies including standard anoscopy, anal cytology, and HPV genotyping in HIV-positive men who have sex with men.
     Br J Cancer. 2018 Jul 20. pii: 10.1038/s41416-018-0176.
     PubMed     Abstract available
     
     
     
156. PEETERS M, Price T, Taieb J, Geissler M, et al
     Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK
     Br J Cancer. 2018 Jul 17. pii: 10.1038/s41416-018-0165.
     PubMed     Abstract available
     
     
     
157. ROSEWEIR AK, Halcrow ES, Chichilo S, Powell AG, et al
     ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer.
     Br J Cancer. 2018 Jul 10. pii: 10.1038/s41416-018-0174.
     PubMed     Abstract available
     
     
     
158. BERGER AK, Lucke S, Abel U, Haag GM, et al
     Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial.
     Br J Cancer. 2018 Jul 2. pii: 10.1038/s41416-018-0152.
     PubMed     Abstract available
     
     
     June 2018
159. CHOI Y, Kwon CH, Lee SJ, Park J, et al
     Integrative analysis of oncogenic fusion genes and their functional impact in colorectal cancer.
     Br J Cancer. 2018 Jun 29. pii: 10.1038/s41416-018-0153.
     PubMed     Abstract available
     
     
     
160. THOMSEN M, Skovlund E, Sorbye H, Bolstad N, et al
     Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome.
     Br J Cancer. 2018 Jun 6. pii: 10.1038/s41416-018-0115.
     PubMed     Abstract available
     
     
     
161. ZHENG R, Du M, Zhang B, Xin J, et al
     Body mass index (BMI) trajectories and risk of colorectal cancer in the PLCO cohort.
     Br J Cancer. 2018 Jun 6. pii: 10.1038/s41416-018-0121.
     PubMed     Abstract available
     
     
     May 2018
162. MORGAN RG, Mortensson E, Williams AC
     Targeting LGR5 in Colorectal Cancer: therapeutic gold or too plastic?
     Br J Cancer. 2018 May 30. pii: 10.1038/s41416-018-0118.
     PubMed     Abstract available
     
     
     
163. SIRNIO P, Tuomisto A, Tervahartiala T, Sorsa T, et al
     High-serum MMP-8 levels are associated with decreased survival and systemic inflammation in colorectal cancer.
     Br J Cancer. 2018 May 29. pii: 10.1038/s41416-018-0136.
     PubMed     Abstract available
     
     
     
164. NEUMEYER S, Banbury BL, Arndt V, Berndt SI, et al
     Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer.
     Br J Cancer. 2018 May 24. pii: 10.1038/s41416-018-0108.
     PubMed     Abstract available
     
     
     
165. DOLAN RD, McSorley ST, Park JH, Watt DG, et al
     The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores.
     Br J Cancer. 2018 May 23. pii: 10.1038/s41416-018-0095.
     PubMed     Abstract available
     
     
     
166. ZUNDER SM, van Pelt GW, Gelderblom HJ, Mancao C, et al
     Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer.
     Br J Cancer. 2018 May 14. pii: 10.1038/s41416-018-0083.
     PubMed     Abstract available
     
     
     
167. MA R, Xu L, Qu X, Che X, et al
     AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status.
     Br J Cancer. 2018 May 14. pii: 10.1038/s41416-018-0086.
     PubMed     Abstract available
     
     
     April 2018
168. BERGHEIM J, Semaan A, Gevensleben H, Groening S, et al
     Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study.
     Br J Cancer. 2018 Apr 3. pii: 10.1038/s41416-018-0035.
     PubMed     Abstract available
     
     
     March 2018
169. SHINOZAKI E, Yoshino T, Tsuchihara K
     Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Ant
     Br J Cancer. 2018 Mar 22. pii: 10.1038/s41416-018-0040.
     PubMed    
     
     
     
170. DANKNER M, Rose AAN
     Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by
     Br J Cancer. 2018 Mar 22. pii: 10.1038/s41416-018-0012.
     PubMed    
     
     
     
171. CREMOLINI C, Milione M, Marmorino F, Morano F, et al
     Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
     Br J Cancer. 2018 Mar 13. pii: 10.1038/s41416-018-0015.
     PubMed     Abstract available
     
     
     
172. MORRIS JS, Bradbury KE, Cross AJ, Gunter MJ, et al
     Physical activity, sedentary behaviour and colorectal cancer risk in the UK Biobank.
     Br J Cancer. 2018 Mar 8. pii: bjc2017496. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
173. FERNANDEZ-ROZADILLA C, Kartsonaki C, Woolley C, McClellan M, et al
     Telomere length and genetics are independent colorectal tumour risk factors in an evaluation of biomarkers in normal bowel.
     Br J Cancer. 2018;118:727-732.
     PubMed     Abstract available
     
     
     
174. DI GIROLAMO C, Walters S, Gildea C, Benitez Majano S, et al
     Which patients are not included in the English Cancer Waiting Times monitoring dataset, 2009-2013? Implications for use of the data in research.
     Br J Cancer. 2018;118:733-737.
     PubMed     Abstract available
     
     
     
175. PATEL M, McSorley ST, Park JH, Roxburgh CSD, et al
     The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer.
     Br J Cancer. 2018;118:705-712.
     PubMed     Abstract available
     
     
     February 2018
176. MORGAN RG, Mortensson E, Legge DN, Gupta B, et al
     LGR5 expression is regulated by EGF in early colorectal adenomas and governs EGFR inhibitor sensitivity.
     Br J Cancer. 2018;118:558-565.
     PubMed     Abstract available
     
     
     
177. YUZHALIN AE, Urbonas T, Silva MA, Muschel RJ, et al
     A core matrisome gene signature predicts cancer outcome.
     Br J Cancer. 2018;118:435-440.
     PubMed     Abstract available
     
     
     
178. NIEMINEN MT, Listyarifah D, Hagstrom J, Haglund C, et al
     Treponema denticola chymotrypsin-like proteinase may contribute to orodigestive carcinogenesis through immunomodulation.
     Br J Cancer. 2018;118:428-434.
     PubMed     Abstract available
     
     
     January 2018
179. USHER-SMITH JA, Harshfield A, Saunders CL, Sharp SJ, et al
     External validation of risk prediction models for incident colorectal cancer using UK Biobank.
     Br J Cancer. 2018 Jan 30. pii: bjc2017463. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
180. TAPIAL S, Rueda D, Arriba M, Luis Garcia J, et al
     Comment on 'Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system'.
     Br J Cancer. 2018 Jan 2. pii: bjc2017343. doi: 10.1038/bjc.2017.
     PubMed    
     
     
     
181. FENG H, Zhao JK, Schiergens TS, Wang PX, et al
     Bone marrow-derived mesenchymal stromal cells promote colorectal cancer cell death under low-dose irradiation.
     Br J Cancer. 2018 Jan 2. pii: bjc2017415. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
182. BAE JM, Kim JH, Kwak Y, Lee DW, et al
     Reply to 'Comment on 'Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system".
     Br J Cancer. 2018 Jan 2. pii: bjc2017426. doi: 10.1038/bjc.2017.
     PubMed    
     
     
     December 2017
183. KIM SR, Song N, Yothers G, Gavin PG, et al
     Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology).
     Br J Cancer. 2017 Dec 14. pii: bjc2017448. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
184. FENG H, Liu Y, Bian X, Zhou F, et al
     ALDH1A3 affects colon cancer in vitro proliferation and invasion depending on CXCR4 status.
     Br J Cancer. 2017 Dec 12. pii: bjc2017363. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
185. DOPESO H, Rodrigues P, Bilic J, Bazzocco S, et al
     Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer.
     Br J Cancer. 2017 Dec 5. pii: bjc2017420. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
186. ALBUQUERQUE A, Pessegueiro Miranda H, Lopes J, Gandara J, et al
     Liver transplant recipients have a higher prevalence of anal squamous intraepithelial lesions.
     Br J Cancer. 2017;117:1761-1767.
     PubMed     Abstract available
     
     
     
187. LIEVRE A, Ouine B, Canet J, Cartier A, et al
     Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.
     Br J Cancer. 2017;117:1819-1827.
     PubMed     Abstract available
     
     
     November 2017
188. PILLOZZI S, D'Amico M, Bartoli G, Gasparoli L, et al
     The combined activation of KCa3.1 and inhibition of Kv11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells.
     Br J Cancer. 2017 Nov 21. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
189. FLOUD S, Barnes I, Verfurden M, Kuper H, et al
     Disability and participation in breast and bowel cancer screening in England: a large prospective study.
     Br J Cancer. 2017;117:1711-1714.
     PubMed     Abstract available
     
     
     
190. KAWAKITA D, Lee YA, Gren LH, Buys SS, et al
     The impact of folate intake on the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort.
     Br J Cancer. 2017 Nov 21. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
191. GOEL A
     IGF-1R: SUMO-ing its weight in chemoresistant colorectal cancer.
     Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
     PubMed    
     
     
     
192. CODONY-SERVAT J, Cuatrecasas M, Asensio E, Montironi C, et al
     Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
     Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
193. GOEY KKH, Elias SG, Hinke A, van Oijen MGH, et al
     Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials.
     Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
194. SCLAFANI F, Brown G, Cunningham D, Wotherspoon A, et al
     Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer.
     Br J Cancer. 2017;117:1478-1485.
     PubMed     Abstract available
     
     
     
195. COOPER JA, Parsons N, Stinton C, Mathews C, et al
     Risk-adjusted colorectal cancer screening using the FIT and routine screening data: development of a risk prediction model.
     Br J Cancer. 2017 Nov 2. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     October 2017
196. MURAKAMI T, Kikuchi H, Ishimatsu H, Iino I, et al
     Tenascin C in colorectal cancer stroma is a predictive marker for liver metastasis and is a potent target of miR-198 as identified by microRNA analysis.
     Br J Cancer. 2017;117:1360-1370.
     PubMed     Abstract available
     
     
     
197. RUZZO A, Graziano F, Galli F, Galli F, et al
     Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
     Br J Cancer. 2017;117:1269-1277.
     PubMed     Abstract available
     
     
     
198. HOU L, Zhu D, Liang Y, Tian X, et al
     Identification of a specific peptide binding to colon cancer cells from a phage-displayed peptide library.
     Br J Cancer. 2017 Oct 24. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
199. THERKILDSEN C, Ladelund S, Smith-Hansen L, Lindberg LJ, et al
     Towards gene- and gender-based risk estimates in Lynch syndrome; age-specific incidences for 13 extra-colorectal cancer types.
     Br J Cancer. 2017 Oct 24. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
200. GOLLINS S, West N, Sebag-Montefiore D, Myint AS, et al
     Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations.
     Br J Cancer. 2017;117:1286-1294.
     PubMed     Abstract available
     
     
     
201. LETELLIER E, Schmitz M, Ginolhac A, Rodriguez F, et al
     Loss of Myosin Vb in colorectal cancer is a strong prognostic factor for disease recurrence.
     Br J Cancer. 2017 Oct 12. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
202. SHINOZAKI E, Yoshino T, Yamazaki K, Muro K, et al
     Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensi
     Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     September 2017
203. GAYARRE J, Martin-Gimeno P, Osorio A, Paumard B, et al
     Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
     Br J Cancer. 2017;117:1048-1062.
     PubMed     Abstract available
     
     
     
204. BROWN JC, Zemel BS, Troxel AB, Rickels MR, et al
     Dose-response effects of aerobic exercise on body composition among colon cancer survivors: a randomised controlled trial.
     Br J Cancer. 2017 Sep 21. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
205. GIAMPIERI R, Puzzoni M, Daniele B, Ferrari D, et al
     First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) tr
     Br J Cancer. 2017 Sep 19. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
206. SCHUBERT SA, Ruano D, Elsayed FA, Boot A, et al
     Evidence for genetic association between chromosome 1q loci and predisposition to colorectal neoplasia.
     Br J Cancer. 2017;117:876-884.
     PubMed     Abstract available
     
     
     August 2017
207. CALLAHAN CL, Schwartz K, Ruterbusch JJ, Shuch B, et al
     Leukocyte telomere length and renal cell carcinoma survival in two studies.
     Br J Cancer. 2017;117:752-755.
     PubMed     Abstract available
     
     
     
208. ALLARD MA, Adam R, Giuliante F, Lapointe R, et al
     Long-term outcomes of patients with 10 or more colorectal liver metastases.
     Br J Cancer. 2017;117:604-611.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: